reports
Abivax to be Added to Nasdaq Biotechnology Index
Abivax to be Added to Nasdaq Biotechnology Index Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025. Didie...
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in I...
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific Evidence: The acceptance of 1 oral presentation, 5 digital oral presentations and 16 posters reflect an expanding dataset for obefazimod, including additional efficacy, safety, and cytokine data from the Phase 3 ABTE...
- Baptiste Salaville
- Jean-François Granjon
- Louis Boujard
- CFA
- Baptiste Salaville
- Jean-François Granjon
- Louis Boujard
- CFA
- Baptiste Salaville
- Olfa Taamallah
- Yan Derocles
- Baptiste Salaville
- Olfa Taamallah
- Yan Derocles
- Benoit Valleaux
- Steven Gould
- Benoit Valleaux
- Steven Gould
Abivax Presents Third Quarter 2025 Financial Results
Abivax Presents Third Quarter 2025 Financial Results Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 2027 PARIS, France, December 15, 2025, 10:05 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today its key financial info...
Intesa Sanpaolo S.p.A.: 1 director
A director at Intesa Sanpaolo S.p.A. sold 8,000 shares at 5.637EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Hugo Boss AG: 2 directors
Two Directors at Hugo Boss AG bought 12,500 shares at between 34.730EUR and 35.000EUR. The significance rating of the trade was 86/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
- Anthony Dick
- Baptiste Salaville
- Michael Foundoukidis
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
RNO RENAULT SA
VOLV B VOLVO AB CLASS B
EO FAURECIA SA
VAC PIERRE & VACANCES SA
DAI DAIMLER AG
POM PLASTIC OMNIUM SE
TYRES NOKIAN RENKAAT OYJ
BOSS HUGO BOSS AG
FR VALEO SE
VOW3 VOLKSWAGEN AG PREF
NDA AURUBIS AG
CIE CIE AUTOMOTIVE S.A.
CPINV CARE PROPERTY INVEST SA
ZAG ZUMTOBEL GROUP AG
RACE FERRARI NV
PIRC PIRELLI & C. S.P.A.
GEST GESTAMP AUTOMOCION S.A.
8TRA TRATON SE
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
STLA STELLANTIS N.V.
DTG DAIMLER TRUCK
IVG IVECO GROUP
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
ALIV SDB AUTOLIV INC.
BRE BREMBO S.P.A.
- Anthony Dick
- Baptiste Salaville
- Michael Foundoukidis
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
RNO RENAULT SA
VOLV B VOLVO AB CLASS B
EO FAURECIA SA
VAC PIERRE & VACANCES SA
DAI DAIMLER AG
POM PLASTIC OMNIUM SE
TYRES NOKIAN RENKAAT OYJ
BOSS HUGO BOSS AG
FR VALEO SE
VOW3 VOLKSWAGEN AG PREF
NDA AURUBIS AG
CIE CIE AUTOMOTIVE S.A.
CPINV CARE PROPERTY INVEST SA
RACE FERRARI NV
PIRC PIRELLI & C. S.P.A.
GEST GESTAMP AUTOMOCION S.A.
8TRA TRATON SE
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
STLA STELLANTIS N.V.
DTG DAIMLER TRUCK
ALVGO VOGO SA
IVG IVECO GROUP
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
ALIV SDB AUTOLIV INC.
BRE BREMBO S.P.A.
- Andreas Riemann
- Elias New
- Philip Hettich
GBT GUERBET SA
CDA COMPAGNIE DES ALPES SA
BOSS HUGO BOSS AG
A1XA4J CARBIOS SA
QDT QUADIENT SA
CAI CA IMMOBILIEN ANLAGEN AG
UBS UBM DEVELOPMENT AG
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
COPN COSMO PHARMACEUTICALS NV
M MED LIFE
WAVE WAVESTONE SA
LOUP SOCIETE L.D.C.
SHA SCHAEFFLER AG
- Elias New
- Philip Hettich
GBT GUERBET SA
CDA COMPAGNIE DES ALPES SA
BOSS HUGO BOSS AG
A1XA4J CARBIOS SA
QDT QUADIENT SA
CAI CA IMMOBILIEN ANLAGEN AG
UBS UBM DEVELOPMENT AG
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
COPN COSMO PHARMACEUTICALS NV
M MED LIFE
WAVE WAVESTONE SA
LOUP SOCIETE L.D.C.
SHA SCHAEFFLER AG
- Andreas Riemann
- Julian Dobrovolschi
- Julian Dobrovolschi
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.